1. Боженко В.К., Харченко Н.В., Запиров Г.М., Кудинова Е.А., Троценко И.Д., Солодкий В.А. Анализ экспрессии генов пролиферации и апоптоза в зависимости от статуса рецепторов стероидных гормонов при раке молочной железы. Вестн. Рос. науч. центра рентгенорадиологии Минздрава России. 2012; 12 (4): 24.
Bozhenko V.K., Kharchenko N.V., Zapirov G.M., Kudinova Ye.A., Trotsenko I.D., Solodkiy V.A. Analysis of the expression of proliferation and apoptosis genes depending on the status of steroid hormone receptors in breast cancer. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii Ministerstva zdravookhraneniya Rossiyskoy Federatsii = Bulletin of the Russian Scientific Center of Roentgenology. 2012; 12 (4): 24. [In Russian].
2. Дергунова Ю.А., Кометова В.В., Боженко В.К., Варданян С.Г., Кулинич Т.М., Родионов В.В., Кудинова Е.А. Сравнение иммуногистохимического и ПЦР метода определения уровня экспрессии Ki-67 в ткани рака молочной железы. Вестн. Рос. науч. центра рентгенорадиологии Минздрава России. 2018; 18 (3): 52–68.
Dergunova Yu.A., Kometova V.V., Bozhenko V.K., Vardanyan S.G., Kulinich T.M., Rodionov V.V., Kudinova E.A. Comparison of immunohistochemical and PCRmethod for determination of Ki-67 expression level in breast cancer tissue. Vestnik Rossiyskogo nauchnogo tsentra rentgenoradiologii Ministerstva zdravookhraneniya Rossiyskoy Federatsii = Bulletin of the Russian Scientific Center of Roentgenology. 2018; 18 (3): 52–6. [In Russian].
3. Брагина О.Д., Слонимская Е.М., Завьялова М.В., Телегина Н.С., Перельмутер В.М., Тарабановская Н.А., Дорошенко А.В. Предсказательное значение ряда молекулярных параметров у больных базальноподобным трипл-негативным раком молочной железы. Сиб. онкол. журн. 2014; (3): 5–10.
Bragina O.D., Slonimskaya E.M., Zavyalova M.V., Telegina N.S., Perelmuter V.M., Tarabanovskaya N.A., Doroshenko A.V. The predictive value of a number of molecular parameters in patients with basal-like triple-negative breast cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology. 2014; (3): 5–10. [In Russian].
4. Стенина М.Б., Фролова М.А., Купчан Д.З., Тюляндин С.А. Изменения в нео- и адъювантном лечении рака молочной железы за последние 5 лет. Практ. онкология. 2017; 18 (3): 256–264.
Stenina M.B., Frolova M.A., Kupchan D.Z., Tyulyandin S.A. Changes in neo- and adjuvant treatment of breast cancer in last 5 years. Prakticheskaya onkologiya = Practical Oncology. 2017; 18 (3): 256–264. [In Russian]. doi: 10.31917/1803256.
5. Чернов В.И., Брагина О.Д., Синилкин И.Г., Тицкая А.А., Зельчан Р.В. Радиоиммунотерапия в лечении злокачественных образований. Сиб. онкол. журн. 2016; 15 (2): 101–106.
Chernov V.I., Bragina O.D., Sinilkin I.G., Titskaya A.A., Zelchan R.V. Radioimmunotherapy in the treatment of malignancies. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology. 2016; 15 (2): 101–106. [In Russian].
6. Babyshkina N., Malinovskaya E., Patalyak S., Bragina O., Tarabanovskaya N., Doroshenko A., Slonimskaya E., Perelmuter V., Cherdyntseva N. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Med. Oncol. 2014; 31 (9): 165. doi: 10.1007/s12032-014-0165-7.
7. Cianfrocca M., Gradishar W. New molecular classifications of breast cancer. CA Cancer J. Clin. 2009; 59 (5): 303–313. doi: 10.3322/caac.20029.
8. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., Senn H.J. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann. Oncol. 2013; 24 (9): 2206–2223. doi: 10.1093/annonc/mdt303.
9. Raica M., Cîmpean A.M., Ceausu R.A., Fulga V., Nica C., Rudico L., Saptefrati L. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Anticancer Res. 2014; 34 (3): 1435–40.
10. Schrijver W.A.M.E., Suijkerbuijk K.P.M., van Gils C.H., van der Wall E., Moelans C.B., van Diest P.J. Receptor conversion in distant breast cancer metastases: A systematic review and meta-analysis. JNCI J. Natl. Cancer Inst. 2018; 110 (6): 568–580. doi: 10.1093/jnci/djx273.
11. Timmer M., Werner J.M., Röhn G., Ortmann M., Blau T., Cramer C., Stavrinou P., Krischek B., Mallman P., Goldbrunner R. Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res. 2017; 37 (9): 4859–4865. doi: 10.21873/anticanres.11894.
12. Untch M., Huober J., Jackisch C., Schneeweiss A., Brucker S.Y., Dall P., Denkert C., Fasching P.A., Fehm T., Gerber B., Janni W., Kühn T., Lüftner D., Möbus V., Müller V., Rody A., Sinn P., Thill M., Thomssen C., Harbeck N., Liedtke C. Initial treatment of patients with primary breast cancer: Evidence, controversies, consensus: spectrum of opinion of German specialists at the 15th international St. Gallen breast cancer conference (Vienna 2017). Geburtshilfe Frauenheilkd. 2017; 77 (6): 633–644. doi: 10.1055/s-0043-111601.
13. Van Hellemond I.E.G., Geurts S.M.E., Tjan-Heijnen V.C.G. Current status of extended adjuvant endocrine therapy in early stage breast cancer. Curr. Treat. Options Oncol. 2018; 19 (5): 26. doi: 10.1007/s11864-018-0541-1.
14. Van Poznak C., Somerfield M.R., Bast R.C., Cristofanilli M., Goetz M.P., Gonzalez-Angulo A.M., Hicks D.G., Hill E.G., Liu M.C., Lucas W., Mayer I.A., Mennel R.G., Symmans W.F., Hayes D.F., Harris L.N. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2015; 33 (24): 2695–2704. doi: 10.1200/JCO.2015.61.1459.
15. Vorobyeva A., Bragina O., Altai M., Mitran B., Orlova A., Shulga A., Proshkina G., Chernov V., Tolmachev V., Deyev S. Comparative evaluation of radioiodine and technetium-labeled DARPin 9_29 for radionuclide molecular imaging of HER2 expression in malignant tumors. Contrast Media Mol. Imaging. 2018; 2018: 6930425. doi: 10.1155/2018/6930425.
16. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., Allison K.H., Allred D.C., Bartlett J.M., Bilous M., Fitzgibbons P., Hanna W., Jenkins R.B., Mangu P.B., Paik S., Perez E.A., Press M.F., Spears P.A., Vance G.H., Viale G., Hayes D.F. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 2014; 138 (2): 241–256. doi: 10.5858/arpa.2013-0953-SA.
17. Yeung C., Hilton J., Clemons M., Mazzarello S., Hutton B., Haggar F., Addison C.L., Kuchuk I., Zhu X., Gelmon K., Arnaout A. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours – a review. Cancer Metastasis Rev. 2016; 35 (3): 427–437. doi: 10.1007/s10555-016-9631-3.
18. Zavyalova M., Vtorushin S., Krakhmal N., Savelieva O., Tashireva L., Kaigorodova E., Perelmuter V., Telegina N., Denisov E., Bragina O., Slonimskaya E., Choynzonov E. Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes. Experim. Oncol. 2016; 38 (2): 122–127. doi: 10.31768/2312-8852.